Skip to content

The clinical study comparing the effectiveness and safety of transjugular intrahepatic portosystemic shunts with endoscopic treatment for the prevention of esophagogastric variceal bleeding in porto-sinusoidal vascular disorder combined with esophagogastric varices bleeding

The clinical study comparing the effectiveness and safety of transjugular intrahepatic portosystemic shunts with endoscopic treatment for the prevention of esophagogastric variceal bleeding in porto-sinusoidal vascular disorder combined with esophagogastric varices bleeding

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068531
Enrollment
Unknown
Registered
2023-02-22
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Porto-sinusoidal vascular disorder

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 75 years; 2. Diagnosed PSVD based on clinical manifestations, laboratory and imaging examinations and liver histopathological biopsy.

Exclusion criteria

Exclusion criteria: 1. Diagnosed liver cirrhosis or other non-cirrhotic portal hypertension diseases(such as congenital hepatic fibrosis, Budd-chiari syndrome, sinusoidal obstruction syndrome) based on histopathological biopsy; 2. Previous TIPS or surgical shunt; 3. With other complications related to portal hypertension(such as refractory ascites, hepatorenal syndrome and hepetopulmonary syndrome); 4. Child-Pugh score is greater than 12; 5. Uncontrolled EGVB or stabilized for less than one week; 6. With infection before operation; 7. Recurrent attacks of hepatic encephalopathy(more than 2 times); 8. Dysfunction of organs including heart, lung, kidney and brain, and pulmonary hypertension; 9. Liver cancer and other malignant tumors beyond Milan criteria; 10. Pregnant and lactating women;

Design outcomes

Primary

MeasureTime frame
Complications related to portal hypertension;Blood biochemical indices;Hepatic encephalopathy;Refractory ascites;Infections;Liver failure;

Countries

China

Contacts

Public ContactHao Wu

West China Hospital, Sichuan University

594264513@qq.com+86 18980601287

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026